<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433509</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH101-IRB1-114</org_study_id>
    <nct_id>NCT02433509</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke</brief_title>
  <official_title>Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>StemCyte, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saneron CCEL Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the safely of Human Umbilical Cord Blood
      mononuclear cells by Intravenous injection in acute ischemic stroke patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will use Umbilical Cord Blood cells (a special kind of cell that is believed to be
      a stem cell) isolated from UCB (blood obtained at birth from the umbilical cord blood of
      babies). StemCyte, a leading accredited UCB banking company with branches in the United
      States and Taiwan, will provide the units of UCB that match at least 6 out of 6 HLA (human
      leukocyte antigens) for transplantation. The HLA-matching is the same as that used to match
      cells and organs for transplantation so that the body does not reject the cells. Then cells
      injection by Intravenous in acute ischemic stroke patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>acute ischemic stroke</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events (AE)and serious adverse reaction(SAE)</measure>
    <time_frame>after infusion 24, 48, 72 hours , 1 week or discharge , and 1, 3, 6 , 9, 12 months.</time_frame>
    <description>any AE or SAE (related or non-related) during the 12-month follow-up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain Image(MRI)</measure>
    <time_frame>baseline, after infusion 24 hours, 1, 6, 12months</time_frame>
    <description>changes of Brain Images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal sonography-spleen</measure>
    <time_frame>baseline, after infusion 24, 72 hours, 3, 12months</time_frame>
    <description>size changes of spleen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>baseline, after infusion 24, 48, 72 hours, 1weeks or discharge, 1 3, 6, 9, 12months</time_frame>
    <description>neurology functions change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg Balance score</measure>
    <time_frame>baseline, after infusion 24, 48, 72 hours, 1weeks or discharge, 1 3, 6, 9, 12months</time_frame>
    <description>motor function changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>baseline, after infusion 24, 48, 72 hours, 1weeks or discharge, 1 3, 6, 9, 12months</time_frame>
    <description>neurology function changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood examination</measure>
    <time_frame>baseline, after infusion 24, 48, 72 hours, 1 3, 6, 9, 12months</time_frame>
    <description>physical condition monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytokine family</measure>
    <time_frame>baseline, after infusion 24, 48, 72 hours, 1 3, 6, 9, 12months</time_frame>
    <description>for study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>HUCB cells combine with Mannitol treatment in acute stroke</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cord blood need to be infusion within 72 hours after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.
20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion .</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Human Umbilical Cord Blood mononuclear cells and 20% mannitol</intervention_name>
    <description>The cord blood need to be infusion within 72 hours after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.
20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion .</description>
    <arm_group_label>HUCB cells combine with Mannitol treatment in acute stroke</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The age of Subjects between 45 through 80 years.

          2. Acute Ischemic Stroke.

          3. National Institutes of Health Stroke Scale (NIHSS):8-18(left brain ) or 8-15(right
             brain )

          4. Brain MRI shows the middle cerebral artery region (M1 and M2) of cerebral i infarction
             stroke patients.

          5. Subjects have no midline shift or hemorrhagic transformation

        Exclusion Criteria:

          1. NIHSS score reduced more than 4 within after 12~24 hours.

          2. Female are pregnant or lactating.

          3. Subjects with impaired liver function, AIDS, cancer or other significant medical
             condition (including certifiable diseases, rare disease)

          4. Subjects joined other clinical trails or received rt-PA therapy.

          5. Immune dysfunction or receiving other immunosuppressive agents.

          6. Subjects cannot have MRI test

          7. Subjects' HLA typing results match less than 6 out of the 6 genotypes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shinn-Zong Lin, M.D.;PhD.</last_name>
    <role>Study Director</role>
    <affiliation>China Medical University Beigand Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shinn-Zong Lin, M.D.;PhD.</last_name>
    <phone>886-5-7837901</phone>
    <phone_ext>1204</phone_ext>
    <email>shinnzong@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>China Medical University Beigang Hospital</name>
      <address>
        <city>Beigang</city>
        <state>Yunlin</state>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shinn-zong Lin, M.D.;PhD.</last_name>
      <phone>886-5-7837901</phone>
      <phone_ext>1204</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Buddhist Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Shinn-Zong Lin</investigator_full_name>
    <investigator_title>Professor of Neurosurgery, China Medical University hospital</investigator_title>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>umbilical cord blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

